Bladder Cancer Drug Pipeline Update
|出版商||BioSeeker Group AB||商品編碼||167165|
Amerian Cancer Society指出，美國膀胱癌為第六位之癌症。接受早期治療之5年存活率有94％。
According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate is 94%.
There are today 139 companies plus partners developing 152 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 42 drugs. Bladder Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 142 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 136 out of the 138 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 48 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug name & Synonyms
Target Expression Profile
Principal Company & Partners
Target and Molecular Function of Target
Fillings and Approvals
Phase IV Data
Phase III Data
Phase II Data
Phase I Data
Phase 0 Data
Dynamic Report Generator